BioSpace News Archive

SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).

Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster presentation at the 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, in San Diego, CA.

Tevogen Bio Holdings has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.

Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today reported financial results for the full year ended December 31, 2023, and additional business updates.

Zai Lab Limited partner Novocure announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields therapy and supportive care compared to supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cancer following stereotactic radiosurgery.

Olympus announced the appointment of Julien Sauvagnargues to the role of President and Chief Executive Officer, Olympus Corporation of the Americas, reporting to Olympus Chief Strategy Officer, Gabriela Kaynor, effective April 1, 2024.

Cantargia Cantargia reported on the progress in the upcoming phase Ib/IIa clinical trial investigating nadunolimab in up to 40 patients with acute myeloid leukemia or myelodysplastic syndrome.

Blackstone announced a new collaboration with Moderna, Inc. through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences will provide up to $750 million to fund Moderna’s influenza program.

SyntheticMR announced that their next-generation imaging solution with isotropic resolution, SyMRI 3D, has received FDA 510 clearance for clinical use in the United States.

EDAP TMS SA, the global leader in robotic energy-based therapies, reported unaudited financial results for the fourth quarter and full-year 2023.